These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 6795742)

  • 1. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process.
    Mason EC; Pepper DS; Griffin B
    Thromb Haemost; 1981 Aug; 46(2):543-6. PubMed ID: 6795742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryoprecipitate of intermediate purity produced in a closed thaw-siphon system from DDAVP stimulated blood donor plasma.
    Konecka G; Bykowska K; Ludwicka A; Letowska M; Wegrzynowicz Z; Sablinski J; Lopaciuk S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(4):565-70. PubMed ID: 1714861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An improved thaw-siphon method for the cryoprecipitate preparation.
    Kang EP
    Vox Sang; 1980; 38(3):172-7. PubMed ID: 6770544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
    Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
    Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in factor VIII complex activities during the production of a clinical intermediate purity factor VIII concentrate.
    Prowse CV; Griffin B; Pepper DS; Dickson AJ; McQuillan TA; Dickson IH; Foster PR
    Thromb Haemost; 1981 Oct; 46(3):597-601. PubMed ID: 6797090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
    Toolis F; McKay G; Prowse CV
    Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased yield of F VIII from pooled plasma vs. single-donor plasma in the production of cryoprecipitates.
    Rácz Z; Thék M; Jánossy A; Pintér J; Baróti C
    Arch Med Res; 1997; 28(2):179-82. PubMed ID: 9204605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of storage of whole blood on the association of factor VIII-related antigen and factor VIII-coagulant antigen.
    Hellings JA; Over J; van Mourik JA
    Scand J Haematol; 1982 Nov; 29(5):353-62. PubMed ID: 6818685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII-related activities in therapeutic concentrates.
    Barrowcliffe TW; Kemball-Cook G; Morris G; Holt JC; Furlong RA; Peake IR
    J Lab Clin Med; 1981 Mar; 97(3):429-38. PubMed ID: 6780643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VIII fractionation on aminohexyl Sepharose with possible reduction in hepatitis B antigen.
    Austen DE; Smith JK
    Thromb Haemost; 1982 Aug; 48(1):46-8. PubMed ID: 6813994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII.
    Foster PR; Dickson AJ; McQuillan TA; Dickson IH; Keddie S; Watt JG
    Vox Sang; 1982; 42(4):180-9. PubMed ID: 6806984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protocol for the preparation of cryoprecipitate and cryodepleted plasma.
    Sparrow RL; Greening DW; Simpson RJ
    Methods Mol Biol; 2011; 728():259-65. PubMed ID: 21468954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. von Willebrand factor contained in factor VIII concentrates of different purities supports platelet adhesion in blood samples from a heterogeneous group of patients with von Willebrand disease.
    Escolar G; Carretero M; Magallón M; Quintana M; Arnau C; Castillo R; Aznar-Salatti J
    Haematologica; 1998 Nov; 83(11):1009-14. PubMed ID: 9864923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII.
    Mason EC
    Lancet; 1978 Jul; 2(8079):15-7. PubMed ID: 78212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP; Smid WM; van der Does JA; van der Meer J; Briët E
    Thromb Haemost; 1996 Feb; 75(2):261-6. PubMed ID: 8815573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of a therapeutic concentrate of factor VIII/vWf prepared in a closed system].
    Mazurier C; Maillard J; Parquet-Gernez A; Goudemand M
    Rev Fr Transfus Immunohematol; 1982 Feb; 25(1):25-43. PubMed ID: 6803339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Possibilities to elevate the factor VIII yield].
    Uteg KH; Tausendfreund K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(1):153-69. PubMed ID: 2439416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
    Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
    Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
    Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
    Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the 'Mason' (continuous-thaw-siphon) method for cryoprecipitate production.
    Prowse CV; McGill A
    Vox Sang; 1979; 37(4):235-43. PubMed ID: 386613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.